

Fourth Quarter 2024 Performance Summary

February 2025



TOTAL REVENUE

\$736 M +20% y/y¹

TYVASO DPI[®]
(treprostinil) INHALATION POWDER

TYVASO[®]
(treprostinil) INHALATION SOLUTION

Tyvaso²

\$416M +19% y/y

REMODULIN[®]
(treprostinil) Injection

Remodulin

\$135M +17% y/y

Orenitram[®]
treprostinil
EXTENDED-RELEASE TABLETS

Orenitram

\$108M +28% y/y

Unituxin[®]
(dinutuximab) Injection

Unituxin

\$68M +25% y/y



TTM OPERATING
CASH FLOW

\$1.3 billion



CASH, CASH EQUIVALENTS,
& MARKETABLE INVESTMENTS

\$4.7 billion

Quarterly Highlights

**United
Therapeutics**
A PUBLIC BENEFIT CORPORATION

**17th consecutive
quarter of y/y
revenue growth**

TYVASO DPI[®]
(treprostinil) INHALATION POWDER

TYVASO[®]
(treprostinil) INHALATION SOLUTION

- **Most prescribed U.S. prostacyclin**
- **Record patient shipments**

REMODULIN[®]
(treprostinil) Injection

- **Most prescribed U.S. parenteral prostacyclin**
- **Record patient shipments**




orenitram[®]
treprostinil
EXTENDED-RELEASE TABLETS

- **Twelfth sequential quarter of quarterly y/y revenue growth**

Unituxin[®]
(dinutuximab) Injection

- **Record total and U.S. revenue**
- **The most prescribed antibody therapy for high-risk neuroblastoma in the U.S.**

Quarterly Revenue, millions USD



NASDAQ

UTHR

2024 Financials

PRODUCT REVENUE

~\$2.9 billion

REVENUE/EMPLOYEE

~\$2.2 million

FOUNDED

1996

HQ

**Research Triangle Park, NC
Silver Spring, MD**

EMPLOYEES

>1,300⁴

1. y/y = year over year. 2. Tyvaso DPI + nebulized Tyvaso. 3. CAGR = compound annual growth rate calculated from 4Q/19 to 4Q/24. 4. As of 12/31/2024

Pipeline

Development Engine Addressing Unmet Needs

	Non-Registration	Registration	Filed	Approved
Tyvaso				
TETON 1 - Idiopathic Pulmonary Fibrosis - U.S. and Canada				
TETON 2 - Idiopathic Pulmonary Fibrosis - ROW ¹				
TETON PPF - Progressive Pulmonary Fibrosis				
Ralinepag				
ADVANCE OUTCOMES - PAH ²				
Xeno, Organs, and Organ Alternatives				
EVLP ³ /CLES ⁴ - Lung Transplant				
UKidney™ - End Stage Renal Disease ⁶				
miroliverELAP ⁵ - Acute Liver Failure				


Pre-clinical Xeno and Organ Alternative Programs

UThymoKidney™	UHeart™	ULung™	miroliver®
ULobe™	IVIVA Kidney	mirokidney®	

Pipeline Spotlights

TETON 1 FULLY ENROLLED	TETON 2 FULLY ENROLLED	UKIDNEY™ IND CLEARED
Data Expected 1H26	Data Expected 2H25	First Transplant Expected Mid-25

Positioned for Multiple Waves of Growth⁷



This Fact Sheet contains forward-looking statements that are subject to risks and uncertainties, which are described in greater detail at ir.unither.com/disclaimer

1. ROW = rest of world outside the U.S. and Canada. 2. PAH = pulmonary arterial hypertension. 3. EVLP = ex-vivo lung perfusion. 4. CLES = centralized lung evaluation system. 5. ELAP = external liver assist product. 6. Registrational status pending agreement with the FDA. 7. Illustrative purposes only

Learn More



United Therapeutics'
Corporate Website



United Therapeutics'
Investor Relations Website



United Therapeutics'
LinkedIn



United Therapeutics'
Corporate Responsibility
Website

